This inventor holds 2 USPTO granted patents. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2012-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012-2013
Title: Innovations of Juan Miguel Jimenez
Introduction
Juan Miguel Jimenez is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors of protein kinases. With a total of 2 patents to his name, his work has the potential to impact the treatment of various diseases and conditions.
Latest Patents
Jimenez's latest patents include "Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases." This invention relates to compounds that are effective in inhibiting protein kinase activity. The patent also encompasses pharmaceutically acceptable compositions that include these compounds and methods for their use in treating various disorders. Another significant patent is "Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof." This invention details a process for synthesizing 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine with high yield and purity, which is crucial for developing biologically active compounds, particularly certain GSK-3 inhibitors.
Career Highlights
Juan Miguel Jimenez is currently associated with Vertex Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on creating effective treatments that can significantly improve patient outcomes.
Collaborations
Jimenez has collaborated with notable colleagues such as Andrew Miller and Philip Collier, contributing to a dynamic research environment that fosters innovation and development.
Conclusion
Juan Miguel Jimenez is a prominent inventor whose work in the pharmaceutical industry is paving the way for new treatments. His patents reflect a commitment to advancing medical science and improving health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
